<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36916674</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Predictors of severe hemolytic anemia and its impact on major outcomes in systemic lupus erythematosus: Data from a multiethnic Latin American cohort.</ArticleTitle><Pagination><StartPage>658</StartPage><EndPage>667</EndPage><MedlinePgn>658-667</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231163745</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the predictors of the occurrence of severe autoimmune hemolytic anemia (AIHA) and its impact on damage accrual and mortality in SLE patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Factors associated with time to severe AIHA (hemoglobin level &#x2264;7&#xa0;g/dL) occurring from the onset of SLE symptoms were examined by Cox proportional hazards regressions. The association of severe AIHA with mortality was examined by logistic regression analyses while its impact on damage was by negative binomial regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 1,349 patients, 49 (3.6%) developed severe AIHA over a mean (SD) follow-up time of 5.4 (3.8) years. The median time from the first clinical manifestation to severe AIHA was 111&#xa0;days (IQR 43-450). By multivariable analysis, male sex (HR 2.26, 95% CI 1.02-4.75, <i>p</i> = 0.044), and higher disease activity at diagnosis (HR 1.04, 95% CI 1.01-1.08, <i>p</i> = 0.025) were associated with a shorter time to severe AIHA occurrence. Of the SLEDAI descriptors, only hematologic (leukopenia and/or thrombocytopenia) showed a certain trend toward significance in the multivariable analysis (HR 2.36, 95% CI 0.91-6.13, <i>p</i> = 0.0772). Severe AIHA contributed neither to damage nor to mortality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Severe AIHA occurs during the early course of SLE. Male sex and higher disease activity at diagnosis emerged as independent predictors of a shorter time to severe AIHA occurrence. Although not statistically significant, hematological abnormalities at SLE diagnosis could predict the occurrence of severe AIHA in a shorter time. Damage and mortality did not seem to be impacted by the occurrence of severe AIHA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>Luis Alonso</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-6523-3919</Identifier><AffiliationInfo><Affiliation>Divisi&#xf3;n de Reumatolog&#xed;a, Departamento de Medicina Interna, Facultad de Medicina, Universidad de Antioquia, Medellin, Colombia.</Affiliation><Identifier Source="RINGGOLD">27983</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alarc&#xf3;n</LastName><ForeName>Graciela S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0001-5190-9175</Identifier><AffiliationInfo><Affiliation>Division of Clinical Immunology and Rheumatology, Department of Medicine, Marnix E. Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Universidad Peruana Cayetano, Heredia, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Guillermina B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Escuela de Estad&#xed;stica, Facultad de Ciencias Econ&#xf3;micas y Estad&#xed;stica, Universidad Nacional de Rosario, Rosario, Argentina.</Affiliation><Identifier Source="RINGGOLD">488296</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintana</LastName><ForeName>Rosana</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0643-2755</Identifier><AffiliationInfo><Affiliation>Grupo Oro&#xf1;o, Centro Regional de Enfermedades Autoinmunes y Reum&#xe1;ticas (GO-CREAR), Rosario, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pons-Estel</LastName><ForeName>Guillermo J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0002-0647-929X</Identifier><AffiliationInfo><Affiliation>Grupo Oro&#xf1;o, Centro Regional de Enfermedades Autoinmunes y Reum&#xe1;ticas (GO-CREAR), Rosario, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ugarte-Gil</LastName><ForeName>Manuel F</ForeName><Initials>MF</Initials><Identifier Source="ORCID">0000-0003-1728-1999</Identifier><AffiliationInfo><Affiliation>Rheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Per&#xfa;.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo Peruano de Estudio de Enfermedades Autoinmunes Sist&#xe9;micas, Universidad Cient&#xed;fica del Sur, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;squez</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n de Reumatolog&#xed;a, Departamento de Medicina Interna, Facultad de Medicina, Universidad de Antioquia, Medellin, Colombia.</Affiliation><Identifier Source="RINGGOLD">27983</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catoggio</LastName><ForeName>Luis J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</Affiliation><Identifier Source="RINGGOLD">37533</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Mercedes A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0003-4773-9112</Identifier><AffiliationInfo><Affiliation>Servicio de Reumatolog&#xed;a, HIGA San Martin de La Plata, Buenos Aires, Argentina.</Affiliation><Identifier Source="RINGGOLD">37533</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borba</LastName><ForeName>Eduardo F</ForeName><Initials>EF</Initials><Identifier Source="ORCID">0000-0001-6194-5129</Identifier><AffiliationInfo><Affiliation>Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Da Silva</LastName><ForeName>Nilzio A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Faculdade de Medicina da Universidad e Federal de Goias, Goiania, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavares Brenol</LastName><ForeName>Jo&#xe3;o C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Hospital de Cl&#xed;nicas de Porto Alegre, Porto Alegre, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.</Affiliation><Identifier Source="RINGGOLD">28124</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toledano</LastName><ForeName>Marlene Guibert</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Servicio Nacional de Reumatolog&#xed;a, Centro de Investigaciones M&#xe9;dico Quir&#xfa;rgicas (CIMEQ), La Habana, Cuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massardo</LastName><ForeName>Loreto</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4790-1258</Identifier><AffiliationInfo><Affiliation>Centro de Biolog&#xed;a Celular y Biomedicina (CEBICEM), Facultad de Medicina y Ciencia, Universidad San Sebasti&#xe1;n, Santiago de Chile, Chile.</Affiliation><Identifier Source="RINGGOLD">373328</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neira</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Secci&#xf3;n de Reumatolog&#xed;a, Hospital del Salvador, Universidad de Chile, Santiago, Chile.</Affiliation><Identifier Source="RINGGOLD">476601</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascual-Ramos</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n "Salvador Zubir&#xe1;n", Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amigo</LastName><ForeName>Mary-Carmen</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-2255-3138</Identifier><AffiliationInfo><Affiliation>Reumatolog&#xed;a, Centro M&#xe9;dico ABC, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barile-Fabris</LastName><ForeName>Leonor A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Hospital &#xc1;ngeles del Pedregal, Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De La Torre</LastName><ForeName>Ignacio Garc&#xed;a</ForeName><Initials>IG</Initials><Identifier Source="ORCID">0000-0002-9261-678X</Identifier><AffiliationInfo><Affiliation>Departamento de Inmunolog&#xed;a y Reumatolog&#xed;a, Hospital General de Occidentede la S.S. y Universidad de Guadalajara, Zapopan, Jalisco, M&#xe9;xico.</Affiliation><Identifier Source="RINGGOLD">37758</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alfaro-Lozano</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segami</LastName><ForeName>Mar&#xed;a I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Hospital Nacional "Edgardo Rebagliati Martins", Essalud, Lima, Per&#xfa;.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chac&#xf3;n-D&#xed;az</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centro Nacional de Enfermedades Reum&#xe1;ticas, Hospital Universitario de Caracas, Caracas, Venezuela.</Affiliation><Identifier Source="RINGGOLD">198370</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esteva-Spinetti</LastName><ForeName>Mar&#xed;a H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Servicio de Reumatolog&#xed;a, Departamento de Medicina, Hospital Central de San Crist&#xf3;bal, San Crist&#xf3;bal, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iglesias-Gamarra</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Reumatolog&#xed;a, Departamento de Medicina Interna, Universidad Nacional de Colombia, Bogot&#xe1;, Colombia.</Affiliation><Identifier Source="RINGGOLD">28021</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pons-Estel</LastName><ForeName>Bernardo A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Grupo Oro&#xf1;o, Centro Regional de Enfermedades Autoinmunes y Reum&#xe1;ticas (GO-CREAR), Rosario, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007843" MajorTopicYN="N" Type="Geographic">Latin America</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006630" MajorTopicYN="N">Hispanic or Latino</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000744" MajorTopicYN="Y">Anemia, Hemolytic, Autoimmune</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007970" MajorTopicYN="Y">Leukopenia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">autoimmune hemolytic anemia</Keyword><Keyword MajorTopicYN="N">ethnicity</Keyword><Keyword MajorTopicYN="N">predictors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36916674</ArticleId><ArticleId IdType="doi">10.1177/09612033231163745</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>